Prelude Capital Management, LLC Cellectis S.A. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $56,520 - $75,024	-3,600 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $29,556 - $75,672	3,600 New	3,600 $64,000
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $7,815 - $13,005	-770 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $11,242 - $15,862	770 New	770 $12,000
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $62,320 - $113,640	-4,000 Closed	0 $0

Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $10,396 - $12,240	400 Added 11.11%	4,000 $113,000
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $30,558 - $42,383	1,100 Added 44.0%	3,600 $102,000
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $2,778 - $3,519	100 Added 4.17%	2,500 $79,000
Q4 2017 Feb 14, 2018	BUY	$23.33 - $35.01 $9,332 - $14,004	400 Added 20.0%	2,400 $70,000
Q3 2017 Nov 14, 2017	BUY	$21.65 - $32.18 $43,300 - $64,360	2,000	2,000 $57,000

9.73M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $101M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.